Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: The cause of end-organ damage and acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) patients is postulated to be connected to the uncontrolled increase of pro-inflammatory cytokines. The upregulation of many cytokines is dependent on signaling through the Janus kinase 1 (JAK-1) and JAK-2 pathways. Ruxolitinib, a JAK-1 and JAK-2 inhibitor, is documented to have potent anti-inflammatory activity by targeting several cytokines and growth factors with proposed efficacy in the cytokine storm observed in severe COVID-19 patients; therefore, this study examines the efficacy and tolerability of ruxolitinib for adult COVID-19 patients. Materials and Methods: This review was conducted using preferred reporting items for aystematic reviews and meta-analyses (PRISMA) methodology. Six reviewers analyzed 1,120 results. Seven studies were selected and validated. A quantitative meta-analysis was further performed to evaluate clinical improvement at day 28, mortality at day 28, and oxygen requirements comparing treatment and standard of care groups. Results: 168 individuals were involved in the studies selected: 122 in cohort studies, 4 in case reports, and 41 in randomized controlled studies. The ruxolitinib group had a higher likelihood of clinical improvement by the 28th day of treatment when assessed with the standard of care (SOC) group (odds ratio [OR]: 1.48; 95% confidence interval [CI]: 0.53 - 4.16; P = 0.45; I2 = 0%). The SOC group was at a higher risk of experiencing serious adverse events (OR: 0.17; 95% CI: 0.03 - 1.13; P = 0.07). Notably the SOC group had a higher likelihood of death (OR: 0.51; 95% CI: 0.11-2.29; P = 0.07; I2 = 0%). Conclusion: Prior studies on ruxolitinib have demonstrated it is able to decrease inflammatory markers. In recent studies on COVID-19, treatment with ruxolitinib decreased the time on mechanical ventilation, hospitalization time, and the need for vasopressor support. Additionally, ruxolitinib showed decreased mortality and demonstrated improvement in lung congestion as evidenced by computerized tomography imaging. These findings warrant further clinical investigation into Ruxolitinib as a potential treatment approach for severe COVID-19.
Abstract
Background: The cause of end-organ damage and acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) patients is postulated to be connected to the uncontrolled increase of pro-inflammatory cytokines. The upregulation of many cytokines is dependent on signaling through the Janus kinase 1 (JAK-1) and JAK-2 pathways. Ruxolitinib, a JAK-1 and JAK-2 inhibitor, is documented to have potent anti-inflammatory activity by targeting several cytokines and growth factors with proposed efficacy in the cytokine storm observed in severe COVID-19 patients; therefore, this study examines the efficacy and tolerability of ruxolitinib for adult COVID-19 patients. Materials and Methods: This review was conducted using preferred reporting items for aystematic reviews and meta-analyses (PRISMA) methodology. Six reviewers analyzed 1,120 results. Seven studies were selected and validated. A quantitative meta-analysis was further performed to evaluate clinical improvement at day 28, mortality at day 28, and oxygen requirements comparing treatment and standard of care groups. Results: 168 individuals were involved in the studies selected: 122 in cohort studies, 4 in case reports, and 41 in randomized controlled studies. The ruxolitinib group had a higher likelihood of clinical improvement by the 28th day of treatment when assessed with the standard of care (SOC) group (odds ratio [OR]: 1.48; 95% confidence interval [CI]: 0.53 - 4.16; P = 0.45; I2 = 0%). The SOC group was at a higher risk of experiencing serious adverse events (OR: 0.17; 95% CI: 0.03 - 1.13; P = 0.07). Notably the SOC group had a higher likelihood of death (OR: 0.51; 95% CI: 0.11-2.29; P = 0.07; I2 = 0%). Conclusion: Prior studies on ruxolitinib have demonstrated it is able to decrease inflammatory markers. In recent studies on COVID-19, treatment with ruxolitinib decreased the time on mechanical ventilation, hospitalization time, and the need for vasopressor support. Additionally, ruxolitinib showed decreased mortality and demonstrated improvement in lung congestion as evidenced by computerized tomography imaging. These findings warrant further clinical investigation into Ruxolitinib as a potential treatment approach for severe COVID-19.
참고문헌 (23)
- "Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update"[URL]
- Chen G, "Clinical and immunological features of severe and moderate coronavirus disease 2019", J Clin Invest, 130, pp.2620~2629 (2020)
- Huang C, ". Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Luo W, "Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19", Trends Pharmacol Sci, 41, pp.531~543 (2020)
- La Rosée F, "The Janus kinase 1", 2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation, 2020, pp.34, 1805~1815
- Elli EM, "Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib", Front Oncol, 9, pp.1186~ (2019)
- Harrison C, "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis", N Engl J Med, 366, pp.787~798 (2012)
- Ahmed A, "Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial", Lancet Haematol, 6, pp.e630~e637 (2019)
- Zeiser R, "uxolitinib for glucocorticoidrefractory acute graft-versus-host disease", N Engl J Med, 382, pp.1800~1810 (2020)
- Ankathatti Munegowda M, "Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery", Cell Biosci, 5, pp.29~ (2015)
- Keohane C, "JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells", Br J Haematol, 171, pp.60~73 (2015)
- Alschuler L, "Integrative considerations during the COVID-19 pandemic", Explore (NY), 16, pp.354~356 (2020)
- Zhang C, "Cytokine release syndrome in severe COVID-19: interleukin-6receptor antagonist tocilizumab may be the key to reduce mortality", Int J Antimicrob Agents, 55, pp.105954~ (2020)
- Catanzaro M, "Immune response in COVID-19:addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2", Signal Transduct Target Ther, 5, pp.84~ (2020)
- Yeleswaram S, "Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment", Clin Immunol, 218, pp.108517~ (2020)
- Giudice V, "Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: A controlled study", Front Pharmacol, 11, pp.857~ (2020)
- Cao Y, "Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial", J Allergy Clin Immunol, 146, pp.137~146.e3 (2020)
- Saraceni F, ". Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib", Transpl Infect Dis, 23, pp.e13401~ (2021)
- Koschmieder S, "Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis", Eur J Haematol, 105, pp.655~658 (2020)
- Portsmore S, "Combined IL-6 and JAK", STAT inhibition therapy in COVID-19-related sHLH, potential game changer, 2020, pp.190, 525~528
- Innes AJ, "Ruxolitinib for tocilizumab-refractory severe COVID-19 infection", Br J Haematol, 190, pp.e198~e200 (2020)
- Capochiani E, "Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection from RESPIRE protocol", Front Med (Lausanne), 7, pp.466~ (2020)
- Sammartano V, "Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant)", Leuk Lymphoma, 61, pp.3523~3525 (2020)